Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19094370 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | March 2025 | April 2025 | Allow | 1 | 0 | 0 | Yes | No |
| 19072385 | POLQ INHIBITORS | March 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19070930 | RAS INHIBITORS | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19069098 | MACROCYCLIC DERIVATIVE AND USE THEREOF | March 2025 | June 2025 | Allow | 3 | 0 | 1 | No | No |
| 19063141 | NOVEL COMPOUNDS | February 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19062331 | RAS INHIBITORS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19054180 | GLP-1R AGONIST COMPOUND AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19052553 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19053277 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | February 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19050547 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19042986 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19040329 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | January 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19039220 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | January 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 19038538 | WRN INHIBITORS | January 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 19038543 | WRN INHIBITORS | January 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19038532 | WRN INHIBITORS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19030481 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | January 2025 | June 2025 | Abandon | 5 | 1 | 0 | No | No |
| 19024709 | USE OF REBOXETINE TO TREAT NARCOLEPSY | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19020085 | INHIBITORS OF KIF18A AND USES THEREOF | January 2025 | June 2025 | Allow | 5 | 0 | 1 | No | No |
| 19020776 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19020628 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018731 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19018788 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018805 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018817 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018754 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018773 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19016827 | SUBSTITUTED QUINAZOLINES AS HDAC6 INHIBITORS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19015403 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19003381 | ORGANOSELENIUM BENZIMIDAZOLE COMPOUNDS FOR TREATING CANCER | December 2024 | March 2025 | Allow | 2 | 0 | 0 | No | No |
| 19002491 | Compounds | December 2024 | May 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19001374 | Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient Opening | December 2024 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19000200 | KRAS G12D MODULATING COMPOUNDS | December 2024 | May 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18999331 | ACYLSULFONAMIDE KAT6A INHIBITORS | December 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18999662 | EPINEPHRINE COMPOSITIONS AND CONTAINERS | December 2024 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18990351 | METHODS OF IMPROVING RENAL FUNCTION | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18987568 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 18988163 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Abandon | 6 | 1 | 0 | No | No |
| 18988090 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Abandon | 6 | 1 | 0 | No | No |
| 18988636 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | December 2024 | May 2025 | Allow | 5 | 1 | 0 | No | No |
| 18986934 | METHOD OF TREATING CANCER WITH A SELENIDE | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18985720 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | December 2024 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18986415 | Method of treating post-traumatic stress disorder with carpipramine | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18980700 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | December 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18978995 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | December 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18977370 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18974530 | Preparation Method and Application of Micelle Preparation Containing Thymol and Derivative Thereof | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18973867 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | December 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18973849 | LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATION | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18972557 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | December 2024 | April 2025 | Allow | 5 | 0 | 1 | No | No |
| 18968101 | SUBSTITUTED PHENYL OXAZOLONE COMPOUNDS | December 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18968074 | EMULSIFIABLE NEONICOTINOID PESTICIDE CONCENTRATE | December 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18968441 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | December 2024 | March 2025 | Allow | 3 | 1 | 1 | No | No |
| 18958628 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18958449 | Compositions And Methods For The Treatment Of Depression | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18868756 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | November 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18956941 | COMPOSITIONS AND METHODS FOR TREATING CANCER | November 2024 | June 2025 | Allow | 6 | 1 | 1 | No | No |
| 18955261 | PHENETHYLAMINES AND CATHINONES PRECURSORS | November 2024 | February 2025 | Allow | 3 | 0 | 0 | No | No |
| 18952842 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHECKPOINT INHIBITOR-RESISTANT TUMORS USING PLINABULIN-BASED COMBINATION THERAPIES | November 2024 | June 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18951509 | PLEUROMUTILIN ONIUM SALT DERIVATIVE CONTAINING A 3H-IMIDAZO[4,5-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOF | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18949105 | PARTICULATE COMPOSITION | November 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18948031 | CRYSTALLINE FORMS OF 4-ETHOXY-N-(2-METHOXYETHYL)-N-METHYL-3-(5-METHYL-4-OXO-7-PROPYL-3,4-DIHYDROIMIDAZO[5,1-f][1,2,4]TRIAZIN-2-YL)BENZENESULFONAMIDE | November 2024 | February 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18865727 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | November 2024 | April 2025 | Allow | 5 | 0 | 0 | No | No |
| 18947694 | Liquid Tasimelteon Formulations and Methods of Use Thereof | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18946234 | FORMULATION PRODUCTION PROCESS | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18945079 | TREATMENT OF MIGRAINE | November 2024 | June 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18945317 | GLABRIDIN COMPOSITION WITH HIGH SKIN PERMEABILITY, AND PREPARATION METHOD AND USE THEREOF | November 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18943210 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | November 2024 | March 2025 | Allow | 4 | 0 | 0 | No | No |
| 18941779 | USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18941137 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18939592 | CYTOTOXIC TREATMENT OF CANCER CELLS | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18938926 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | November 2024 | May 2025 | Allow | 6 | 1 | 1 | No | No |
| 18938942 | Oral Testosterone Therapy | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18937891 | TREATMENT OF PROSTATE CANCER | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18934931 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | November 2024 | February 2025 | Allow | 4 | 0 | 1 | No | No |
| 18932827 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | October 2024 | May 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18932033 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | October 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18927346 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18927756 | BENZOTRIAZOLE COMPOUND | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18926907 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | October 2024 | February 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18925543 | 2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2024 | June 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18924415 | TREATMENT OF MIGRAINE | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18919625 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18920212 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | October 2024 | March 2025 | Allow | 5 | 0 | 1 | No | No |
| 18917653 | NLRP3 INFLAMMASOME INHIBITORS | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18916471 | METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18914691 | ARYL-1,2,3-TRIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR TREATMENT OF BREAST CANCER | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18915221 | AZAINDOLE ROCK INHIBITORS | October 2024 | January 2025 | Allow | 3 | 0 | 0 | No | No |
| 18913645 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | October 2024 | April 2025 | Allow | 6 | 1 | 1 | No | No |
| 18913072 | METHODS OF TREATING MIGRAINE | October 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18854563 | RUTHENIUM PRECURSOR COMPOSITION, PREPARATION METHOD THEREFOR, AND FORMATION METHOD FOR RUTHENIUM-CONTAINING FILM USING SAME | October 2024 | February 2025 | Allow | 4 | 0 | 0 | No | No |
| 18905898 | METHOD OF TREATING HAIR LOSS DISORDERS | October 2024 | March 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18905502 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18905534 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18905520 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18904487 | ROCAGLATE DERIVATIVES AND USES THEREOF | October 2024 | February 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18903345 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | October 2024 | December 2024 | Allow | 2 | 1 | 0 | Yes | No |
| 18901359 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | September 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18901530 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | September 2024 | May 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18899500 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1620.
With a 29.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1620 is part of Technology Center 1600. This group has examined 176,947 patent applications in our dataset, with an overall allowance rate of 68.2%. Applications typically reach final disposition in approximately 24 months.
Applications in Group 1620 receive an average of 1.50 office actions before reaching final disposition. The median prosecution time is 24 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.